Specialist comments

Comments on this technology were invited from clinical experts working in the field and relevant patient organisations. The comments received are individual opinions and do not represent NICE's view.

Three specialists contributed to this briefing, 2 were familiar with the technology and 1 had used this technology before.

Level of innovation

All the specialists agreed that EarlyCDT‑Lung has not been superseded. One of them noted that currently no blood test is used to manage indeterminate pulmonary nodules (IPN). One specialist felt the technology is innovative because it can allow early detection of lung cancer. Another specialist felt EarlyCDT‑Lung could reduce cases for PET scans and speed up the pathways. This specialist also noted the EarlyCDT‑Lung could be used for follow up.

Potential patient impact

One specialist stated that EarlyCDT‑Lung can improve IPN management because there is a move towards implementing lung cancer screening. This specialist also highlighted that, although a biopsy is the gold standard diagnostic test, invasive testing is associated with risks such as pneumothorax and bleeding. Two specialists felt that patient exposure to CT scans would be reduced, as well as lessening anxieties over false positive results. Another noted that the early detection of malignant tumour is a potential benefit to the patient. One specialist noted that people with IPN who have comorbidities will benefit from EarlyCDT‑Lung. Another felt people in socioeconomically deprived areas will benefit. One specialist noted that it would be interesting to know what effect early detection has on survival rates for people in the Scottish lung cancer screening study that has used EarlyCDT‑Lung.

Potential system impact

All the specialists agreed that EarlyCDT‑Lung can improve the current pathway for IPN. One noted that if EarlyCDT‑Lung can improve precision of estimate from existing risk-based models then patient management can be improved. Another felt earlier diagnosis in 35% to 40% of cases is likely to improve disease management.

General comments

All clinical specialists agreed that there is need for further robust evidence to support the technology. One specialist noted that a reduction in lung imaging may have globally significant implications for case finding and screening for lung cancer in people at high risk of the disease.